Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-cell lymphoma 2-associated athanogene 3–Interferon-induced transmembrane protein 2 protein–protein interaction (BAG3–IFITM2 PPI) (BAG3–IFITM2 PPI)
- Target
- BAG3–IFITM2 PPI
- Molecular classification
- Protein-protein interaction, Co-chaperone, Transmembrane protein
01
Overview
The B-cell lymphoma 2-associated athanogene}
- Other names
- BAG3-IFITM2 axisBAG3-IFITM2 complexExtracellular BAG3-IFITM2 interaction
02
Mechanism of action
Neutralization of extracellular BAG3 to prevent its binding to the IFITM2 receptor on macrophages, thereby inhibiting the activation of the PI3K/AKT/NF-κB signaling pathway and the subsequent release of pro-tumorigenic cytokines.
03
Biological functions
Signal transductionCytokine productionCell survivalImmune modulationApoptosis regulation
04
Disease associations
Pancreatic cancerInflammationTumor microenvironment modulation
05
Safety considerations
Potential cardiotoxicity due to the essential role of intracellular BAG3 in maintaining cardiomyocyte structural integrity and function [3, 6]Potential interference with IFITM2-mediated viral restriction and innate immune responses [4]Therapeutic window challenges between extracellular and intracellular BAG3 pools
06
Interacting drugs
Anti-BAG3 monoclonal antibody (BAG3-mAb)
07
Biomarkers
Serum soluble BAG3 (sBAG3) levelsIFITM2 expression on tumor-associated macrophagesBAG3 expression in pancreatic ductal adenocarcinoma tissue
Beyond the preview
Go deeper on B-cell lymphoma 2-associated athanogene 3–Interferon-induced transmembrane protein 2 protein–protein interaction (BAG3–IFITM2 PPI) (BAG3–IFITM2 PPI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B-cell lymphoma 2-associated athanogene 3–Interferon-induced transmembrane protein 2 protein–protein interaction (BAG3–IFITM2 PPI) (BAG3–IFITM2 PPI).